Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 23;29(3):1349-1369.
doi: 10.3390/curroncol29030115.

The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study

Gina Wong  1 , Katie Wang  1 , Mark Pasetka  1 , Liying Zhang  2 , Julia Lou  2 , Habeeb Majeed  1 , Jerome Flores  3 , Emily Lam  1 , Carlo DeAngelis  1
Affiliations

The Real-World Experience of the Biosimilar (Grastofil®) to the Reference Biologic (Neupogen®) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study

Gina Wong et al. Curr Oncol. .

Abstract

Febrile neutropenia (FN) is a common side effect of cytotoxic chemotherapy that may result in poor treatment outcomes. The short acting granulocyte colony stimulating factors (G-CSF) act to stimulate granulocytes to increase production of white blood cells. The filgrastim biosimilar is useful, as it may provide a cheaper and equally effective treatment to FN. This study explored the usage of the filgrastim biosimilar (Grastofil®) and the reference biologic (Neupogen®) in breast cancer and lymphoma patients. A retrospective chart review of patients receiving Grastofil® from January 2017 to June 2019 or Neupogen® for primary prophylaxis of FN from January 2013 to December 2017 was conducted. The endpoints included the incidence of FN and the occurrence of dose reduction (DR) and dose delay (DD). One hundred and fifty-three Grastofil® patients were matched to 153 Neupogen® patients. This cohort was further split into breast cancer (n = 275) and non-Hodgkin's lymphoma (n = 31) cohorts. After adjusting for chemotherapy cycles, the biosimilar filgrastim was non-inferior to the reference biologic based on FN incidence in addition to related outcomes including DR and DD.

Keywords: Neupogen® and Grastofil®; biosimilar; breast cancer; febrile neutropenia; lymphoma; primary prophylaxis; retrospective study.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Exclusion criteria to determine cohorts.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Weycker D., Barron R., Edelsberg J., Kartashov A., Legg J., Glass A.G. Risk and Consequences of Chemotherapy-Induced Neutropenic Complications in Patients Receiving Daily Filgrastim: The Importance of Duration of Prophylaxis. BMC Health Serv. Res. 2014;14:189. doi: 10.1186/1472-6963-14-189. - DOI - PMC - PubMed
    1. Crawford J., Caserta C., Roila F. ESMO Guidelines Working Group. Hematopoietic Growth Factors: ESMO Clinical Practice Guidelines for the Applications. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2010;21((Suppl. 5)):v248–v251. doi: 10.1093/annonc/mdq195. - DOI - PubMed
    1. Smith T.J., Bohlke K., Lyman G.H., Carson K.R., Crawford J., Cross S.J., Goldberg J.M., Khatcheressian J.L., Leighl N.B., Perkins C.L., et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2015;33:3199–3212. doi: 10.1200/JCO.2015.62.3488. - DOI - PubMed
    1. Klastersky J., de Naurois J., Rolston K., Rapoport B., Maschmeyer G., Aapro M., Herrstedt J., on behalf of the ESMO Guidelines Committee Management of Febrile Neutropaenia: ESMO Clinical Practice Guidelines. Ann. Oncol. 2016;27((Suppl. 5)):v111–v118. doi: 10.1093/annonc/mdw325. - DOI - PubMed
    1. Lyman G.H., Dale D.C., Culakova E., Poniewierski M.S., Wolff D.A., Kuderer N.M., Huang M., Crawford J. The Impact of the Granulocyte Colony-Stimulating Factor on Chemotherapy Dose Intensity and Cancer Survival: A Systematic Review and Meta-Analysisof Randomized Controlled Trials. Ann. Oncol. 2013;24:2475–2484. doi: 10.1093/annonc/mdt226. - DOI - PMC - PubMed

Publication types

MeSH terms